X-Chem

October 15, 2020

Clinical setback lays bare Vertex’s weakness

As the company is punished for its failure to diversify, could it be forced into making an acquisition?

June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data

Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

April 26, 2019

Astra’s first attempt fails, but there’s no giving up on KRAS

After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.

X-Chem

Clinical setback lays bare Vertex’s weakness

Asco 2019 – KRAS chase heats up with Amgen data

Astra’s first attempt fails, but there’s no giving up on KRAS

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

Evaluate Vantage 2021 Preview

Editor's Picks

2020 wins top of the froths for biotech stocks

Biotech flotations remain in high demand

Glaxo’s growth problem

Go or no go? Oncology decisions ahead for the FDA

Pfizer reveals its PD-1 secret